Opdivo Qvantig in India
How patients in India access Opdivo Qvantig (nivolumab) via Named Patient Program.
Opdivo Qvantig - overview
Opdivo Qvantig (nivolumab) is manufactured by Bristol Myers Squibb and indicated for approved across most solid tumor indications for which IV nivolumab is approved, see full prescribing information. It is a subcutaneous PD-1 inhibitor co-formulated with hyaluronidase approved by the US FDA in 2024 and may be accessible to patients in India through a Named Patient Program or personal-import pathway.
Access in India
India's CDSCO permits import of unapproved drugs under Rule 36 for personal use by patients with a prescription from a registered medical practitioner. Named Patient import is common for rare-disease indications.
How Reserve Meds coordinates access in India
- Patient or treating physician submits a request.
- We verify clinical appropriateness and India-specific eligibility.
- Treating physician in India issues prescription and clinical justification.
- Country-specific NPP/personal-import forms are prepared and filed.
- We source Opdivo Qvantig from a DSCSA-compliant US specialty wholesaler.
- Cold-chain shipment to the patient's physician or hospital pharmacy in India.
Typical timeline for India
End-to-end, most requests are completed in 2-6 weeks. India's tier 1 regulatory maturity typically supports fast processing times.
What patients and physicians in India ask
- Is the pathway legal in India? Yes - it operates under India's established NPP or personal-import framework.
- Does my insurance cover it? Typically no for NPP drugs; patient prepayment is standard.
- What physician credentials do I need? A licensed physician in India able to issue the prescription and clinical justification.
- What if the drug is in shortage? We will inform you upfront and decline rather than promise what we cannot deliver.
- Can I re-supply? Yes - for chronic therapies we arrange ongoing re-supply.